Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland. The transaction, valued at US $122.5 million, was executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO service agreement with MacroGenics.
With this acquisition, Bora Biologics, the biologics CDMO franchise of Bora Group, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites in Rockville, Maryland and San Diego, California, along with a development facility in Zhubei, Taiwan. The expanded platform supports more than four active commercial programs, with over 120 completed GMP batches supplying markets including the US, EU, Japan, Canada, and the UK. The combined network features fully integrated QC and analytical capabilities.
Bobby Sheng, Chairman and CEO of Bora Group, stated: "This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply. As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
Bora Biologics has completed five FDA inspections, including two at the Rockville facility and one PMDA review in 2025, with clean results at both sites. The platform has supported more than 33 biologics and 15 biosimilars, reducing offshore dependency and providing domestically anchored infrastructure. The company plans to integrate its US drug substance (DS) capabilities with existing sterile drug product (DP) capabilities over the next 12 to 18 months, aiming to offer a seamless, fully integrated development-through-commercial biologics solution.
For more information about Bora Pharmaceuticals, visit https://www.bora-corp.com or https://www.boracdmo.com.
